Is tocilizumab in combination with traditional DMARDs safe and effective for patients with active RA?

Nature Clinical Practice Rheumatology

Volumn 5, Issue 3, 2009, Pages 128-129

  Feist, Eugen ^a   Burmester, Gerd R ^b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATLIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; METHOTREXATE; PLACEBO;

CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HEPATITIS; HUMAN; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; LIPID BLOOD LEVEL; LIVER FAILURE; MONOTHERAPY; NEUTROPENIA; NOTE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIDE EFFECT;

EID: 62849085138     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum1005     Document Type: Note

References (9)

1. Hirano T (1998) Interleukin 6 and its receptor: Ten years later. Int Rev Immunol 16: 249-284
2. Genovese MC et al. (2008) Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58: 2968-2980
3. Nishimoto N et al. (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an X-ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66 1162-1167
4. European Medicines Agency (2008) Meeting highlights from the Committee for Medicinal Products for Human Use, 17-20 November 2008 [http://www.emea.europa.eu/pdfs/human/press/pr/60656608en.pdf] (accessed 5 January 2009)
5. Nishimoto N and Kishimoto T (2006) Interleukin 6: From bench to bedside. Nat Clin Pract Rheumatol 2: 619-626
6. Tamura T et al. (1993) Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 90: 11924-11928
7. Maini RN et al. (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54: 2817-2829
8. Emery P et al. (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67: 1516-1523
9. Smolen JS et al. (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet 371: 987-997